Effect of antibiotic gut microbiota disruption on LPS-induced acute lung inflammation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
05
2020
accepted:
21
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
29
12
2020
Statut:
epublish
Résumé
An increasing body of evidence is indicating that the gut microbiota modulates pulmonary inflammatory responses. This so-called gut-lung axis might be of importance in a whole spectrum of inflammatory pulmonary diseases such as acute respiratory distress syndrome, chronic obstructive pulmonary disease and pneumonia. Here, we investigate the effect of antibiotic disruption of gut microbiota on immune responses in the lung after a intranasal challenge with lipopolysaccharide (LPS). C57Bl/6 mice were treated for two weeks with broad-spectrum antibiotics supplemented to their drinking water. Afterwards, mice and untreated control mice were inoculated intranasally with LPS. Mice were sacrificed 2 and 6 hours post-challenge, after which bronchoalveolar lavage fluid (BALF) and lung tissues were taken. Gut microbiota analysis showed that antibiotic-treated mice had a pronounced reduction in numbers and diversity of bacteria. A modest, but time consistent, significant increase of interleukin (IL)-6 release was seen in BALF of antibiotic treated mice. Release of tumor necrosis factor alpha (TNFα), however, was not statistically different between groups. Antibiotic induced microbiota disruption is associated with alterations in host responses during LPS-induced lung inflammation. Further studies are required to determine the clinical relevance of the gut-lung axis in pulmonary infection and inflammation.
Sections du résumé
BACKGROUND
An increasing body of evidence is indicating that the gut microbiota modulates pulmonary inflammatory responses. This so-called gut-lung axis might be of importance in a whole spectrum of inflammatory pulmonary diseases such as acute respiratory distress syndrome, chronic obstructive pulmonary disease and pneumonia. Here, we investigate the effect of antibiotic disruption of gut microbiota on immune responses in the lung after a intranasal challenge with lipopolysaccharide (LPS).
METHODS/RESULTS
C57Bl/6 mice were treated for two weeks with broad-spectrum antibiotics supplemented to their drinking water. Afterwards, mice and untreated control mice were inoculated intranasally with LPS. Mice were sacrificed 2 and 6 hours post-challenge, after which bronchoalveolar lavage fluid (BALF) and lung tissues were taken. Gut microbiota analysis showed that antibiotic-treated mice had a pronounced reduction in numbers and diversity of bacteria. A modest, but time consistent, significant increase of interleukin (IL)-6 release was seen in BALF of antibiotic treated mice. Release of tumor necrosis factor alpha (TNFα), however, was not statistically different between groups.
CONCLUSION
Antibiotic induced microbiota disruption is associated with alterations in host responses during LPS-induced lung inflammation. Further studies are required to determine the clinical relevance of the gut-lung axis in pulmonary infection and inflammation.
Identifiants
pubmed: 33147273
doi: 10.1371/journal.pone.0241748
pii: PONE-D-20-14015
pmc: PMC7641457
doi:
Substances chimiques
Anti-Bacterial Agents
0
Interleukin-6
0
Lipopolysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241748Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Infect Immun. 2015 Oct;83(10):4003-14
pubmed: 26216419
Int J Biol Sci. 2012;8(9):1281-90
pubmed: 23136556
Nat Med. 2014 Feb;20(2):159-66
pubmed: 24390308
Nat Commun. 2016 Jan 26;7:10410
pubmed: 26811868
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Am J Respir Cell Mol Biol. 2016 Feb;54(2):161-9
pubmed: 26473323
BMJ. 2018 Jun 13;361:k2179
pubmed: 29899036
J Surg Res. 2017 May 1;211:126-136
pubmed: 28501108
Nat Rev Microbiol. 2017 Jan;15(1):55-63
pubmed: 27694885
PLoS One. 2010 Apr 16;5(4):e10183
pubmed: 20419140
Gut. 2016 Apr;65(4):575-83
pubmed: 26511795
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2235-40
pubmed: 26858424
Nat Microbiol. 2016 Jul 18;1(10):16113
pubmed: 27670109
Biotechniques. 2004 May;36(5):808-12
pubmed: 15152600
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Expert Rev Respir Med. 2010 Dec;4(6):773-83
pubmed: 21128752
Blood. 2017 Feb 9;129(6):729-739
pubmed: 27879260
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Nature. 2016 Jul 06;535(7610):65-74
pubmed: 27383981
J Infect Dis. 2015 Jan 1;211(1):156-65
pubmed: 25139019
PLoS Negl Trop Dis. 2017 Apr 19;11(4):e0005548
pubmed: 28422970
Crit Care. 2018 Oct 29;22(1):282
pubmed: 30373626